CQDM and Neurenati Therapeutics Fund the Development of an Innovative Treatment against Hirschsprung Disease Montreal, February 29, 2024 – On this International Rare Disease Day, CQDM is proud to announce the funding of a collaborative research project aimed to develop a revolutionary therapeutical approach for Hirschsprung disease. This project with a total value of over…
CQDM Supports the Development of Three Promising Innovations in the Fight Against Cancer with Biopharmaceutical Companies Theratechnologies, Saydi Biotech and Roche. Montreal, February 4, 2024 – On this World Cancer Day, CQDM is proud to contribute to the fight against this global scourge by announcing the funding of three R&D projects made possible thanks to…
Challenge: The storage and worldwide distribution of vaccines represent complex issues for pharmaceutical companies due to vaccine instability at ambient temperatures. Spray drying is an established industrial processing technology for stabilizing many products as dried powders. Although studies have shown spray drying to be promising for preparing thermally stable vaccines in order to alleviate cold…
Challenge: The most critical step in discovering future medications is the identification of the initial hit compounds (“leads”) that interact with target proteins, and which have the desired properties. The search for and validation of potential lead compounds is a major challenge for launching drug discovery programs as this process requires highly specialized expertise, expensive equipment…
Challenge: Cancers with metastases are responsible for 90% of cancer deaths. Unfortunately, metastases often become refractory to treatment and although certain molecules are theoretically able to act on these tumors, their non-targeted administration greatly limits their effectiveness. Solution: This project aims to validate the efficacy of the peptide-drug (TH1902) on secondary tumors by characterizing its mechanisms of…
Challenge: Despite improvements in the treatment of many pediatric cancers, high-risk subtypes such as acute myeloid leukemia (AML) and acute megakrayoblastic leukemia (AMKL) still have amongst the worst prognosis, with only ~40-60% survival at 5-years. There is therefore a critical unmet medical need for novel targeted treatments but to completely eradicate the tumor cells these treatments…
Challenge: The Chimeric Antibody Receptor (CAR) presents a promising avenue in cancer immunotherapy by engineering patients’ T cells to express CAR molecules, enabling targeted recognition and elimination of tumor cells. While CAR-T therapy has demonstrated notable success in inducing remission for B cell leukemia, lymphoma, and multiple myeloma, it has failed in non-hematologic solid tumors, with…
Challenge: Acute leukemia is the most common blood cancer in children. Aggressive chemotherapy and radiation treatments cure about 80% of affected children. However, they are not perfect cures since a part of children is incurable and dies of leukemia and these treatments kill not only the cancer cells, but also the healthy ones. As a result,…
Challenge: The knowledge gained in cancer immunology has increased the list of new therapeutic applications. Yet, these approaches (CAR-T, check-point inhibitors and others) are still suffering from several drawbacks, among them: very high cost, more complex biological or/and cellular-based technologies, lack of efficiency against solid tumours, difficulties in validating multiple combination therapies, increased difficulty in selection…
Challenge: Nerve blocks have revolutionized anesthesia and surgery as well as chronic pain management. They provide better pain relief, significantly reduce the need for opioids, thus impacting on the problem of opioid addiction, speed up recovery from surgery, as well as shorten hospital stay. However, they require special training as well as regular skills maintenance. Very…